Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Shares Outstanding (Weighted Average) (2016 - 2025)

Perspective Therapeutics' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $73.6 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 18.21% year-over-year to $73.6 million; the TTM value through Sep 2025 reached $73.6 million, up 18.21%, while the annual FY2024 figure was $64.4 million, 140.72% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $73.6 million at Perspective Therapeutics, down from $74.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $228.6 million in Q1 2023 and bottomed at $25.4 million in Q2 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $74.2 million (2025), against an average of $98.9 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) crashed 82.08% in 2023 before it skyrocketed 140.72% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $142.0 million in 2021, then rose by 0.08% to $142.1 million in 2022, then tumbled by 81.16% to $26.8 million in 2023, then surged by 140.72% to $64.4 million in 2024, then grew by 14.3% to $73.6 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Shares Outstanding (Weighted Average) are $73.6 million (Q3 2025), $74.2 million (Q2 2025), and $72.4 million (Q1 2025).